Critical Analysis: Meihua International Medical Technologies (NASDAQ:MHUA) and Biotricity (NASDAQ:BTCY)

Biotricity (NASDAQ:BTCY) and Meihua International Medical Technologies (NASDAQ:MHUA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Biotricity and Meihua International Medical Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.47	-$14.09 million	($1.32)	-0.20
Meihua International Medical Technologies	$94.25 million	0.20	$11.62 million	N/A	N/A

Meihua International Medical Technologies has higher revenue and earnings than Biotricity.

Profitability

This table compares Biotricity and Meihua International Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-117.42%	N/A	-242.92%
Meihua International Medical Technologies	N/A	N/A	N/A

Risk & Volatility

Biotricity has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Meihua International Medical Technologies has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Biotricity and Meihua International Medical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
Meihua International Medical Technologies	0	0	0	0	N/A

Institutional and Insider Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 10.0% of Biotricity shares are owned by company insiders. Comparatively, 66.6% of Meihua International Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Meihua International Medical Technologies beats Biotricity on 5 of the 8 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About Meihua International Medical Technologies

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.